MedTrace Logo

Prognostic Molecular Markers in Patients With Myelodysplastic Syndrome

NCT02060409 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 58

Last updated 2014-02-12

No results posted yet for this study

Summary

In the era of hypomethylating agent in MDS treatment, the investigators aimed to investigate the prognostic impact of mutations in spliceosome machinery genes (SRSF2, U2AF1, and ZRSR2) on the outcomes of 1st line decitabine treatment in MDS.

Conditions

Interventions

GENETIC

spliceosome

spliceosome mutations

Sponsors & Collaborators

  • Samsung Medical Center

    lead OTHER

Principal Investigators

  • Jun Ho Jang, MD PhD · Samsung Medical Center

Eligibility

Min Age
17 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-01-31
Primary Completion
2013-10-31
Completion
2014-02-28

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02060409 on ClinicalTrials.gov